Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-CD19 T cell (Kang YU)
- Development stage
- Phase 1
- Lead developer
- Kang Yu
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CAR-CD19 T cell (Kang YU) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting the CD19 antigen. Developed by investigator Kang Yu, typically associated with the Affiliated Hospital of Xuzhou Medical University, this therapy involves the ex vivo genetic modification of a patient's own T cells to express a CAR comprising an anti-CD19 single-chain variable fragment (scFv) linked to intracellular signaling domains (such as 4-1BB and CD3-zeta). The treatment is designed to induce a targeted immune response against CD19-expressing malignant B cells. It is currently being investigated in a Phase 1 pilot study (NCT04106076) for B-cell lymphoblastic leukemia and B-cell lymphoma. The broader clinical program also evaluates separate CAR-T products targeting BCMA, GPC3, and Claudin 18.2 for indications including multiple myeloma, hepatocellular carcinoma, and gastrointestinal adenocarcinomas.
- Other names
- Autologous CAR-CD19 T cells
02
Targets
Beyond the preview
Go deeper on CAR-CD19 T cell (Kang YU).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-CD19 T cell (Kang YU).